GSK plc (NYSE:GSK) Shares Acquired by Americana Partners LLC

Americana Partners LLC grew its stake in GSK plc (NYSE:GSK - Free Report) by 160.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,088 shares of the pharmaceutical company's stock after acquiring an additional 29,043 shares during the quarter. Americana Partners LLC's holdings in GSK were worth $1,727,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Callahan Advisors LLC acquired a new stake in GSK during the third quarter worth $1,119,000. Horizon Bancorp Inc. IN increased its position in shares of GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company's stock worth $147,000 after purchasing an additional 323 shares during the last quarter. Avantax Advisory Services Inc. raised its holdings in GSK by 23.6% in the 3rd quarter. Avantax Advisory Services Inc. now owns 76,840 shares of the pharmaceutical company's stock valued at $2,785,000 after buying an additional 14,689 shares during the period. Kestra Private Wealth Services LLC boosted its stake in GSK by 18.9% during the third quarter. Kestra Private Wealth Services LLC now owns 25,754 shares of the pharmaceutical company's stock worth $934,000 after buying an additional 4,101 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in shares of GSK by 64.7% during the third quarter. Envestnet Asset Management Inc. now owns 1,625,585 shares of the pharmaceutical company's stock valued at $58,927,000 after acquiring an additional 638,544 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Down 0.8 %

Shares of NYSE:GSK traded down $0.34 during trading on Monday, hitting $40.86. The company's stock had a trading volume of 1,856,118 shares, compared to its average volume of 3,513,908. GSK plc has a fifty-two week low of $33.33 and a fifty-two week high of $43.84. The business has a 50 day moving average price of $42.00 and a two-hundred day moving average price of $38.58. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. The company has a market capitalization of $84.67 billion, a PE ratio of 13.58, a P/E/G ratio of 1.87 and a beta of 0.64.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The company had revenue of $10 billion during the quarter, compared to analysts' expectations of $9.79 billion. As a group, research analysts expect that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Investors of record on Friday, February 23rd will be paid a dividend of $0.3564 per share. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.49%. This is a positive change from GSK's previous quarterly dividend of $0.34. The ex-dividend date of this dividend is Thursday, February 22nd. GSK's dividend payout ratio is presently 52.82%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Citigroup upgraded shares of GSK from a "neutral" rating to a "buy" rating in a report on Tuesday, February 13th. Jefferies Financial Group raised GSK from a "hold" rating to a "buy" rating in a research note on Wednesday, January 3rd. Morgan Stanley began coverage on GSK in a research note on Tuesday, January 23rd. They set an "equal weight" rating on the stock. Finally, Guggenheim raised GSK from a "neutral" rating to a "buy" rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy".

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.